A Phase 4 interventional study of speech therapy only and hyperbaric oxygen therapy in Stuttering, Childhood, sponsored by Sohag University. Status unknown. Open to participants aged 5 Years to 15 Years. Per ClinicalTrials.gov, last updated 2022-03-22.
Sponsored by Sohag University · Phase 4, Interventional, and Treatment
The aim of work is comparing between three different methods for treatment of stuttering in children in order to reach to the best method for treatment
74 studies on the registry are indexed under Stuttering; 23 are open to participants now.
This study's planned enrollment of 30 is below the median of 44 across 57 interventional studies indexed under Stuttering.
Browse Stuttering studies →Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
will be treated by speech therapy only (fluency shaping).
Behavioral: speech therapy only
will be treated by speech therapy (fluency shaping) plus Hyperbaric oxygen therapy.
Behavioral: speech therapy only · Device: hyperbaric oxygen therapy
will be treated by speech therapy (fluency shaping) plus medical treatment (brain stimulant).
Behavioral: speech therapy only · Drug: medical treatment
fluency shaping technique
chamber system using oxygen with pressure
brain stimulant
Stuttering severity instrument (SSI-3)
rating scale for stuttering severity
Time frame: before therapy
Stuttering severity instrument (SSI-3)
rating scale for stuttering severity
Time frame: post therapy by 3 months
No study locations are listed for this record.
This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.